Literature DB >> 11462242

Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer.

F Baudi1, B Quaresima, C Grandinetti, G Cuda, C Faniello, P Tassone, V Barbieri, R Bisegna, E Ricevuto, S Conforti, A Viel, P Marchetti, C Ficorella, P Radice, F Costanzo, S Venuta.   

Abstract

Several genes have been involved in the pathogenesis of hereditary breast/ovarian cancer (BOC), but mutations in the BRCA1 gene are by far the most recurrent. In this study, we report the identification of a founder mutation in a geographically and historically homogeneous population from Calabria, a south Italian region. A screening performed on 24 patients from unrelated families highlighted the high prevalence of a 5083del19 alteration in the BRCA1 gene, which accounts for 33% of the overall gene mutations. The same mutation was also detected in 4 patients, all of Calabrian origin, referred to us by research centres from the north of Italy. Allelotype analysis, performed on probands and unaffected family members revealed the presence a common allele, therefore suggesting a founder effect due to a common ancestor. Our findings underscore the importance of ethnic background homogeneity in patients' selection and highlight the usefulness of founder mutations as a potential tool for optimisation of preclinical diagnosis in gene carriers and therapeutic approaches in affected individuals. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11462242     DOI: 10.1002/humu.1167

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  16 in total

1.  Identification of a founder BRCA2 mutation in Sardinian breast cancer families.

Authors:  Maria Monne; Giovanna Piras; Patrizia Fancello; Maria Cristina Santona; Antonella Uras; Gennaro Landriscina; Giuseppe Mastio; Attilio Gabbas
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

2.  Clinical interpretation and implications of whole-genome sequencing.

Authors:  Frederick E Dewey; Megan E Grove; Cuiping Pan; Benjamin A Goldstein; Jonathan A Bernstein; Hassan Chaib; Jason D Merker; Rachel L Goldfeder; Gregory M Enns; Sean P David; Neda Pakdaman; Kelly E Ormond; Colleen Caleshu; Kerry Kingham; Teri E Klein; Michelle Whirl-Carrillo; Kenneth Sakamoto; Matthew T Wheeler; Atul J Butte; James M Ford; Linda Boxer; John P A Ioannidis; Alan C Yeung; Russ B Altman; Themistocles L Assimes; Michael Snyder; Euan A Ashley; Thomas Quertermous
Journal:  JAMA       Date:  2014-03-12       Impact factor: 56.272

3.  High Resolution Melting Analysis is Very Useful to Identify BRCA1 c.4964_4982del19 (rs80359876) Founder Calabrian Pathogenic Variant on Peripheral Blood and Buccal Swab DNA.

Authors:  Angelo Minucci; Maria De Bonis; Elisa De Paolis; Leonarda Gentile; Concetta Santonocito; Paola Concolino; Flavio Mignone; Ettore Capoluongo
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

Review 4.  HER2-positive male breast cancer: an update.

Authors:  Laura Ottini; Carlo Capalbo; Piera Rizzolo; Valentina Silvestri; Giuseppe Bronte; Sergio Rizzo; Antonio Russo
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-10-04

5.  Capillary electrophoresis as alternative method to detect tumor genetic mutations: the model built on the founder BRCA1 c.4964_4982del19 variant.

Authors:  Maria De Bonis; Angelo Minucci; Giovanni Luca Scaglione; Elisa De Paolis; Gianfranco Zannoni; Giovanni Scambia; Ettore Capoluongo
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

6.  Plasma Proteomic Profiling in Hereditary Breast Cancer Reveals a BRCA1-Specific Signature: Diagnostic and Functional Implications.

Authors:  Domenica Scumaci; Laura Tammè; Claudia Vincenza Fiumara; Giusi Pappaianni; Antonio Concolino; Emanuela Leone; Maria Concetta Faniello; Barbara Quaresima; Enrico Ricevuto; Francesco Saverio Costanzo; Giovanni Cuda
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

7.  A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?

Authors:  Nicoletta Staropoli; Domenico Ciliberto; Cirino Botta; Lucia Fiorillo; Simona Gualtieri; Angela Salvino; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  J Ovarian Res       Date:  2013-02-06       Impact factor: 4.234

8.  Inherited and acquired alterations in development of breast cancer.

Authors:  Piera Rizzolo; Valentina Silvestri; Mario Falchetti; Laura Ottini
Journal:  Appl Clin Genet       Date:  2011-11-14

9.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

10.  Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families.

Authors:  Mateja Krajc; Erik Teugels; Janez Zgajnar; Guido Goelen; Nikola Besic; Srdjan Novakovic; Marko Hocevar; Jacques De Grève
Journal:  BMC Med Genet       Date:  2008-09-10       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.